ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 671,34
1,34%
Dow Jones
39 134,76
0,77%
DAX
18 254,18
1,03%
Brent Oil
84,895
-0,13%
Bitcoin
64 871,87
0,08%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Carisma Therapeutics Inc (CARM)

  7. Carisma Therapeutics Inc (CARM) Actualités

CARM Carisma Therapeutics Inc

1,06
0,03 (2,91%)
21 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Carisma Therapeutics Inc CARM NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,03 2,91% 1,06 00:06:07
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,03 1,00 1,03 1,01 1,03
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
19/6/202401:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:32EDGAR2Form 8-K - Current report
14/6/202422:30EDGAR2Form 8-K - Current report
13/6/202422:30PRNUSCarisma Therapeutics Announces Adjournment of Annual Meeting..
05/6/202417:45BWCARMILA : Informations relatives au nombre total de droits..
30/5/202413:30PRNUSCarisma Therapeutics to Participate in the Jefferies Global..
29/5/202401:39EDGAR2Form SC 13D/A - General statement of acquisition of..
16/5/202413:30PRNUSCarisma Therapeutics Announces First Patient Dosed in Phase..
09/5/202413:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202413:41EDGAR2Form 8-K - Current report
09/5/202413:30PRNUSCarisma Therapeutics Reports First Quarter 2024 Financial..
08/5/202417:45BWCarmila: Réduction des moyens du contrat de liquidité
08/5/202413:30PRNUSCarisma Therapeutics Presents Preclinical Proof of Concept..
07/5/202417:45BWCARMILA: Information Concerning the Total Number of Voting..
06/5/202413:30PRNUSCarisma Therapeutics to Participate in The Citizens JMP Life..
02/5/202413:30PRNUSCarisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief..
24/4/202423:05PRNUSCarisma Therapeutics Announces Upcoming Presentation at the..
24/4/202418:43BWCarmila : Lancement d’un programme de rachat d’actions pour..
22/4/202422:35PRNUSCarisma Therapeutics to Present New Data at the American..
17/4/202417:45BWCarmila: First-quarter 2024 Financial Information
05/4/202417:45BWCarmila: Information Concerning the Total Number of Voting..
03/4/202413:00PRNUSCarisma Therapeutics to Present at Upcoming Conferences
01/4/202414:35PRNUSCarisma Therapeutics Provides Business Update and Reports..
01/4/202413:00PRNUSCarisma Therapeutics Announces Changes to its Board of..
21/3/202422:00PRNUSCarisma Announces Upcoming Presentations at the American..
15/3/202417:45BWCARMILA : INFORMATION RELATIVE A LA REMUNERATION DES..
08/3/202417:45BWCORRECTING and REPLACING: Carmila: Changes in the..
07/3/202422:05EDGAR2Form SC 13D/A - General statement of acquisition of..
07/3/202419:13BWCARMILA: Changes in the composition of the Board of..
04/3/202417:45BWCarmila: Information Concerning the Total Number of Voting..
28/2/202413:30PRNUSCarisma Therapeutics to Participate in TD Cowen's 44th..
13/2/202417:45BWCarmila: 2023 Annual Results
02/2/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202419:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
02/2/202417:45BWCARMILA: Information Concerning the Total Number of Voting..
16/1/202417:45BWCarmila: Resources Devoted to the Liquidity Contract as of..
08/1/202417:57BWCARMILA: Information Concerning the Total Number of Voting..
21/12/202313:00PRNUSCarisma Therapeutics to Present at the 42nd Annual J.P...
14/12/202313:00PRNUSFirst In Vivo CAR-M Lead Candidate Nominated Under..
05/12/202317:45BWCarmila : Informations relatives au nombre total de droits..
28/11/202313:00PRNUSCarisma Therapeutics Announces FDA Clearance of IND..
22/11/202313:30PRNUSCarisma Therapeutics to Participate in Evercore ISI..
10/11/202320:17BWCarmila : Résiliation du contrat de liquidité avec BNP..
09/11/202317:45BWCARMILA : Informations relatives au nombre total de droits..
09/11/202314:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:42EDGAR2Form 8-K - Current report
09/11/202313:30PRNUSCarisma Therapeutics Reports Third Quarter 2023 Financial..
31/10/202314:25PRNUSCarisma Presents Pre-Clinical Proof of Concept for in vivo..
25/10/202315:11PRNUSCarisma to Present First Results From in vivo CAR-M..
20/10/202317:47BWCarmila: Financial Information as of 30 September 2023

Dernières Valeurs Consultées

NASDAQ
CARM
Carisma Therapeutics
BOV
CRPG5R
CRISTAL PNA
BIT
WOSA25
OSAI Automation System
COIN
ZINUOETH
Zombie Inu [OLD]
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés